Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

From magic bullets to designed multiple ligands.

Richard Morphy1, Corinne Kay, Zoran Rankovic

  • 1Medicinal Chemistry Department, Organon Laboratories, Newhouse, Lanarkshire ML1 5SH, UK. r.morphy@organon.co.uk

Drug Discovery Today
|July 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia.

Blood·2026
Same author

Safety considerations for cereblon-recruiting targeted protein degraders.

Nature reviews. Drug discovery·2026
Same author

Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics.

Nature communications·2025
Same author

LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia.

bioRxiv : the preprint server for biology·2025
Same author

HTS Identifies NUP98-KDM5A-PHD3 Domain Ligands with Novel Scaffolds.

ACS medicinal chemistry letters·2025
Same author

Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target.

Cancer cell·2025

Designing multiple ligands offers superior therapeutic effects over selective drugs. Achieving balanced activity and selectivity remains a key challenge for medicinal chemists developing these advanced compounds.

Area of Science:

  • Medicinal Chemistry
  • Drug Design
  • Pharmacology

Background:

  • Single-target drugs often have limited efficacy and side effect profiles.
  • Multi-target ligand (MTL) design is an emerging strategy in drug discovery.
  • Balancing activity across multiple targets is crucial for therapeutic success.

Purpose of the Study:

  • To explore rational design strategies for multi-target ligands.
  • To identify key challenges in developing compounds with balanced activity and selectivity.
  • To provide insights for the next generation of designed multiple ligands.

Main Methods:

  • Literature analysis of existing designed multiple ligands.
  • Examination of trends in combining structural features from selective ligands.

Related Experiment Videos

  • Evaluation of strategies for achieving balanced target modulation and pharmacokinetic profiles.

    • Main Results:

    • Designed multiple ligands can span diverse targets and target classes.
    • Attaining balanced activity and selectivity is a significant design hurdle.
    • Literature analysis reveals valuable trends for medicinal chemists.

    Conclusions:

    • Multi-target ligand design holds promise for improved therapeutic outcomes.
    • Overcoming design challenges is essential for realizing the potential of these compounds.
    • Further research into rational design approaches will advance the field of medicinal chemistry.